S. Njeru

MEK Inhibitor-Associated Retinopathy Secondary to the Use of Trametinib

Introduction: Mitogen-activated protein kinase (MEK) inhibitors have become an important component in the treatment of patients with BRAF-mutated cancers. Although generally well tolerated, these therapies have been associated with a range of ocular adverse effects. As the use of targeted oncologic therapies continues...